FORM PTO-1594 5. 24.99 R OMB No. 0651-0011 (exp. 4/94) Tab settings $\Rightarrow \Rightarrow \Rightarrow \Rightarrow$ 10105112	R SHEET U.S. DEPARTMENT Patent and
Tab settings □□□▼ 10105112 To the Honorable Commissioner of Patents and Trademarks:	Please record the attached original documents or copy the record
Name of conveying party(ies):	Name and address of receiving party(ies)
TRIANGLE BIOMEDICAL SCIENCES, INC.	Name: THE CIT GROUP/CREDIT FINANCE, INC. Attention:
☐ Individual(s) ☐ Association ☐ General Partnership ☐ Limited Partnership XXXCorporation-State - North Carolina ☐ Other Additional name(s) of conveying party(ies) attached? ☐ Yes XXNo	Internal Address: Regional Credit Manager 301 South Tryon Street Street Address: Two First Union Center City: Charlotte State: NC ZIP: 28202 □ Individual(s) citizenship
3. Nature of conveyance:	☐ Association☐ General Partnership
☐ Assignment ☐ Merger X☐ Security Agreement ☐ Change of Name ☐ Other	☐ Limited Partnership
Execution Date: April 28, 1999	is attached:
4. Application number(s) or patent number(s):	
A. Trademark Application No.(s)	B. Trademark Registration No.(s)
	1634603 - 1991027 - /
Additional numbers at	tached? ☐ Yes XX No
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and registrations involved:
Name: Carruthers & Roth, P.A. Internal Address: Attention: Linda K. Sullivan	7. Total fee (37 CFR 3.41)\$ © Enclosed
	☐ Authorized to be charged to deposit account
Street Address: 235 N. Edgeworth Street	8. Deposit account number:
City: Greensboro State: NC ZIP: 27401	(Attach duplicate copy of this page if paying by deposit account)
00 NOT US 01 FC:481 40.00 @P	E THIS SPACE
2 FC:482 25.00 OP	
	**ROTH, P.A.
Linda K. Sullivan By:	5/18/99 Date
Name of Person Signing Total number of pages including	Signature Date cover sheet, attachments, and document:

Mail documents to be recorded with required cover sheet information to:
REEL: 001903 FRAME: 0976

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT ("Agreement"), is made and entered into this _28 day of April, 1999, between TRIANGLE BIOMEDICAL SCIENCES, INC., a North Carolina corporation ("Company"), and THE CIT GROUP/CREDIT FINANCE, INC., a Delaware corporation ("Lender").

WITNESSETH:

WHEREAS, Company proposes to enter into a certain Financing Agreement, dated of even date herewith (the Financing Agreement, as it may hereafter be amended, modified, supplemented or restated from time to time, being herein called the "Financing Agreement"), with Lender pursuant to which Lender will make loans and extend credit to Company, all as more particularly described therein; and

WHEREAS, as a condition precedent to Lender's entering into the Financing Agreement and making loans and extending credit to Company pursuant thereto, Lender has required the execution of this Agreement by Company in favor of Lender.

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, Company agrees with Lender as follows:

- 1. <u>Defined Terms</u>. All capitalized terms used herein without definition shall have the meaning ascribed to such terms in the Financing Agreement.
- 2. <u>Grant of Security Interest</u>. As security for the payment and performance of the Obligations, Company hereby assigns, grants, transfers and conveys to Lender, for security purposes, all of Company's right, title and interest in, to and under the following property, in each case whether now existing or hereafter acquired or arising and whether registered and unregistered and wherever the same may be located (the "Trademark Collateral"):
 - (a) all state (including common law), federal and foreign trademarks, service marks and trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, logos, other source or business identifiers, domain names, designs and general intangibles of like natures, now existing or hereafter adopted or acquired, together with and including all licenses therefor held by Company (unless otherwise prohibited by any license or related licensing agreement under circumstances where the granting of the security interest would have the effect under applicable law of the termination or permitting termination of the license for breach and where the licensor has elected such termination remedy), and all registrations and recordings thereof, and all applications filed or to be filed in connection therewith, including registrations and applications in the United States Patent and Trademark Office, any State of the United States or any other country or any political subdivision thereof, and all extensions or renewals thereof, including any of the foregoing identified on Schedule A hereto (as the same may be amended, modified or supplemented from time

to time), and the right (but not the obligation) to register claims under any state or federal trademark law or regulation or any trademark law or regulation of any foreign country and to apply for, renew and extend any of the same, to sue or bring opposition or cancellation proceedings in the name of Company or in the name of Lender for past, present or future infringement or unconsented use thereof, and all rights arising therefrom throughout the world (collectively, the "Trademarks");

- (b) all claims, causes of action and rights to sue for past, present or future infringement or unconsented use of any Trademarks and all rights arising therefrom and pertaining thereto;
- (c) all general intangibles related to or arising out of any of the Trademarks and all the goodwill of Company's business symbolized by the Trademarks or associated therewith; and
- (d) all proceeds of any and all of the foregoing Trademark Collateral, including, without limitation, license royalties, rights to payment, accounts receivable, proceeds of infringement suits and all payments under insurance or any indemnity, warranty or guaranty payable by reason or loss or damage to or otherwise with respect to the foregoing Trademark Collateral.
- 3. Representations, Warranties and Covenants of Company. Company represents, warrants and covenants that:
 - (a) The Trademark Collateral is, to the best of its knowledge, subsisting and has not been judged invalid or unenforceable;
 - (b) Except for the shared ownership of the trademark "PolyFin" with a supplier, Company is the sole and exclusive owner of the entire and unencumbered right, title and interest in and to the Trademark Collateral;
 - (c) Company has used, and will continue to use for the duration of this Agreement, proper statutory notice in connection with its use of the Trademark Collateral:
 - (d) Company will maintain the quality of the products associated with the Trademark Collateral, generally at a level consistent with the quality as of the effective date of this Agreement, subject to the introduction of new products from time to time, and product modifications in the ordinary course of business; and
 - (e) Company has the unqualified right to enter into this Agreement and perform its terms and has entered and will enter into written agreements with each of its present and future employees, agents and consultants which will enable it to comply with the covenants herein contained.

2

- 4. <u>Visits and Inspections</u>. Company hereby grants to Lender and its employees and agents the right on prior reasonable notice to Company to visit Company's plants and facilities which manufacture, inspect or store products sold under any of the Trademarks, and to inspect the products and quality control records relating thereto at reasonable times during regular business hours, with as minimal disruption of the Company's operations as necessary. Company shall do any and all acts required by Lender to ensure Company's compliance with paragraph 3(d) of this Agreement.
- 5. Restrictions on Future Agreements. Company agrees that, until all of the Obligations have been satisfied in full and the Financing Agreement has been terminated in writing, it will not without Lender's prior written consent, enter into any agreement which is inconsistent with Company's duties under this Agreement, and Company further agrees that it will not take any action, or permit any action to be taken by others subject to its control, including licensees, or fail to take any action, which would affect the validity and enforcement of the rights granted to Lender under this Agreement.
- 6. <u>After-Acquired Trademark Rights</u>. If, before the Obligations have been satisfied in full, Company shall obtain rights to any new trademarks, or become entitled to the benefit of any trademark application or trademark for any renewal of any Trademark, the provisions of paragraph 1 hereof shall automatically apply thereto, and Company shall give to Lender prompt notice thereof in writing. Company authorizes Lender to modify this Agreement by amending <u>Schedule A</u> to include any future trademarks and trademark applications which are Trademark Collateral under paragraph 1 hereof or this paragraph 6.
- 7. Company's Rights Prior to Event of Default. Unless and until there shall have occurred and be continuing an Event of Default (as defined in the Financing Agreement), Company shall continue to own, and may use and enjoy the Trademark Collateral in connection with its business operations, but only in a manner consistent with the presentation of their current substance, validity and registration; provided, however, for so long as no Event of Default shall exist, Company shall retain the right to abandon any of the Trademarks in the ordinary course of business which are no longer used or useful in the operation of Company's business and which Company deems no longer to have any economic value.
- 8. Remedies Upon Event of Default. If an Event of Default shall have occurred and be continuing, Lender shall have, in addition to all other rights and remedies given it by this Agreement, those allowed by law and, specifically, those of a Lender under the Code. Notice of any sale or other disposition of the Trademark Collateral shall be deemed reasonable and sufficient if given the Company at least ten (10) days before the time of any intended public or private sale or other disposition of any of the Trademark Collateral is to be made.
- 9. <u>Power of Attorney</u>. Company hereby makes, constitutes and appoints Lender and any officer or agent of Lender as Lender may select as Company's true and lawful attorney-infact, with full power to do any or all of the following if an Event of Default shall occur and be continuing: to endorse Company's name on all applications, documents, papers and instruments

3

necessary for Lender to use the Trademark Collateral, or to grant or issue any exclusive or nonexclusive license under the Trademark Collateral to anyone else as necessary for Lender to assign, pledge, convey or otherwise transfer title in or dispose of the Trademark Collateral to anyone else. Company hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney shall be irrevocable until all of the Obligations shall have been satisfied in full and the Financing Agreement shall have been terminated in writing.

- 10. Release of Security Interest. At such time as all of the Obligations shall have been satisfied and paid in full, Lender shall execute and deliver to Company all releases, termination statements, and other instruments as may be necessary or proper to release or reflect the release of Lender's security interest in the Trademark Collateral, including all documentation necessary to reflect such release in the United States Patent and Trademark Office.
- 11. <u>Costs and Expenses</u>. Any and all fees, costs and expenses, of whatever kind or nature, including reasonable attorneys' fees and legal expenses, incurred by Lender in connection with the preparation of this Agreement and all other documents relating hereto and the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in public offices, the payment or discharge of any taxes, counsel fees, maintenance fees, encumbrances or otherwise protecting, maintaining, or preserving the Trademark Collateral, or in defending or prosecuting any actions or proceedings arising out of or related to the Trademark Collateral, shall be borne and paid by Company on demand by Lender and until so paid shall be added to the amount of the Obligations and shall bear interest at the rate prescribed in the Financing Agreement.

12. <u>Litigation and Proceedings</u>.

- (a) Company shall have the duty, through counsel acceptable to Lender, to prosecute diligently any trademark application of the Trademarks pending as of the date of this Agreement or thereafter, other than those discontinued or abandoned in the ordinary course of business, until the Obligations shall have been paid in full and to preserve and maintain all rights in trademark applications and trademarks of the Trademarks in the ordinary course of business. Any expenses incurred in connection with such an application shall be borne by Company. Company shall not abandon any right to file a trademark application, or any pending trademark application or trademark, other than those discontinued or abandoned in the ordinary course of business without the consent of Lender, which consent shall not be unreasonably withheld.
- (b) Lender shall have the right, but shall in no way be obligated, to bring suit in its own name, as the holder of a security interest in the Trademark Collateral, to enforce the Trademarks, and any license thereunder, if an Event of Default shall exist or if Company refuses to bring any such suit after demand by Lender, in which event Company shall at the request of Lender do any and all lawful acts (including bringing suit) and execute any and all proper documents required by Lender in aid of such

4

enforcement and Company shall promptly, upon demand, reimburse and indemnify the Lender for all costs and expenses incurred in the exercise of its rights under this paragraph 12. Nothing herein shall be deemed to prohibit Company from bringing any such suit in its own name at any time that an Event of Default does not exist or if Lender declines to institute suit.

- 13. <u>Lender May Perform</u>. If Company fails to comply with any of its obligations hereunder, Lender may do so in Company's name or in Lender's name, but at Company's expense, and Company agrees to reimburse Lender in full for all expenses, including reasonable attorney's fees, incurred by Lender in prosecuting, defending or maintaining the Trademarks or Lender's interest therein pursuant to this Agreement.
- 14. <u>Severability</u>. The provisions of this Agreement are severable, and if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such jurisdiction, and shall not in any manner affect such clause or provision in any other jurisdiction, or any other clause or provision of this Agreement in any jurisdiction.
- 15. <u>Modification</u>. This Agreement is subject to modification only by a writing signed by the parties, except as provided in paragraph 6 hereof.
- 16. <u>Binding Effect; Benefits</u>. The benefits and burdens of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties.
- 17. <u>Notices</u>. All notices, requests and demands to or upon a party hereto, to be effective, shall be in writing and shall be sent by certified or registered mail, return receipt requested, by personal delivery against receipt, by overnight courier or by facsimile transmission and, unless otherwise expressly provided herein, shall be deemed to have been validly served, given or delivered immediately when delivered against receipt, one (1) Business Day after delivery to an overnight air courier, five (5) Business Days after deposit in the mail, postage prepaid, or, in the case of facsimile transmission, when received (if on a Business Day and, if not received on a Business Day, then on the next Business Day after receipt), addressed as follows:
 - (i) If to Lender, at: THE CIT GROUP/CREDIT FINANCE, INC.

301 South Tryon Street Two First Union Center Charlotte, NC 28202

Attn: Regional Credit Manager Facsimile No.: 704-339-2208

5

(ii) If to Company,

at:

TRIANGLE BIOMEDICAL SCIENCES, INC.

3014 Croasdaile Drive

Durham, North Carolina 27705

Attn: President

Facsimile No.: 919-384-9595

or to such other address as each party may designate for itself by notice given in accordance with this Section 17. Any written notice or demand that is not sent in conformity with the provisions hereof shall nevertheless be effective on the date that such notice is actually received by the noticed party.

- 18. Governing Law; Consent to Forum. This agreement shall be governed by and construed in accordance with the laws of the State of North Carolina.
- WAIVER OF JURY TRIAL. COMPANY AND LENDER EACH WAIVES, TO 19. THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM OF ANY KIND ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE FINANCING AGREEMENT, ANY OF THE LOAN DOCUMENTS, THE OBLIGATIONS OR THE COLLATERAL. COMPANY ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO THE LENDER'S ENTERING INTO THE FINANCING AGREEMENT AND EXTENDING CREDIT TO THE COMPANY THEREUNDER AND THAT THE LENDER IS RELYING UPON THIS WAIVER IN ITS FUTURE DEALINGS WITH THE THE COMPANY WARRANTS AND REPRESENTS THAT IT HAS COMPANY. REVIEWED THE FOREGOING WAIVER WITH ITS LEGAL COUNSEL AND HAS KNOWINGLY AND VOLUNTARILY WAIVED ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

[Signatures Begin on the Next Page]

6

WITNESS the execution hereof on the day and year first above written.

TRIANGLE BIOMEDICAL SCIENCES, INC ("Company")

By: Title President

THE CIT GROUP/CREDIT FINANCE, INC. ("Lender")

By: R. D. M.
Title: Vice Preside

STATE OF NORTH CAROLINA'

COUNTY OF DURHAM

I, <u>CAROL H. LOWANS</u>, a Notary Public of the State and County aforesaid, certify that Jack Hunnell personally appeared before me this day and acknowledged that he is President of TRIANGLE BIOMEDICAL SCIENCES, INC, a North Carolina corporation, and that by authority duly given and as the act of the corporation, the foregoing instrument was signed by him/her in the corporation's name.

WITNESS my hand and official stamp or seal, this 28 day of April, 1999.

Carol D Lowans
Notary Public

My Commission Expires: $12 \cdot 2 \cdot 200/$

STATE OF NORTH CAROLINA

COUNTY OF MICKLENDERS

I, Cathune y Kerley, a Notary Public of the State and County aforesaid, certify that Karl D Murn personally appeared before me this day and acknowledged that he is Vice- President of THE CIT GROUP/CREDIT FINANCE, INC., a Delaware corporation, and that by authority duly given and as the act of the corporation, the foregoing instrument was signed by him/her in the corporation's name.

WITNESS my hand and official stamp or seal, this 28 day of April, 1999.

My Commission Expires: 10/1/2

Catherine y Kerley Notary Public

9

SCHEDULE A TO TRADEMARK SECURITY AGREEMENT

	<u>Trademark</u>	Registration No.	<u>Date</u>
1.	Triangle Biomedical Sciences, Inc.	1634603	February 21, 1991
2.	Shur/Mark	1991027	August 5, 1996

FINANCE/ 42234/003775-16495/KMG 4/27/99

RECORDED: 05/24/1999